Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1 | Y | 1 MK-3475 (pembrolizumab) | 56 | 51 | 15 | 8 | 6 | 0 | 0 | 02/06/2017 | 92 | 40 |
| 51 | 15 | 8 | 6 | 0 | 0 | |||||||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 1 | Y | 1 Adjuvant Arm | 556 | 113 | 57 | 37 | 23 | 7 | 1 | 02/15/2019 | 287 | 128 | |
| 2 Neoadjuvant Pembrolizumab | 108 | 52 | 33 | 14 | 3 | 2 | ||||||||
| 221 | 109 | 70 | 37 | 10 | 3 | |||||||||
| 2 | Y | 3 Surgery | 556 | 194 | 99 | 64 | 39 | 11 | 3 | 02/15/2019 | ||||
| 194 | 99 | 64 | 39 | 11 | 3 | |||||||||
| 3 | Y | 4 Post-Surgery Pembro | 556 | 154 | 78 | 48 | 22 | 9 | 1 | 02/15/2019 | ||||
| 154 | 78 | 48 | 22 | 9 | 1 | |||||||||
| S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 1 | Y | 1 Encorafenib/Binimetinib/Nivolu | 112 | 2 | 2 | 2 | 2 | 0 | 0 | 01/06/2021 | 88 | 42 | |
| 2 Ipilimumab + Nivolumab | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
| 4 | 4 | 4 | 3 | 0 | 0 | |||||||||
| Yes | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1 | E | Total Registrations | 53 | 6 | 4 | 2 | 0 | 0 | 11/03/2015 | 275 | 119 | |
| 53 | 6 | 4 | 2 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 19 | 3 | 2 | 0 | 0 | 0 | 11/03/2015 | |||||
| 19 | 3 | 2 | 0 | 0 | 0 | |||||||||
| EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 39 | 3 | 2 | 0 | 0 | 0 | 03/25/2016 | 173 | 77 | ||
| 39 | 3 | 2 | 0 | 0 | 0 | |||||||||
| No | EA6174-Merkel, Adjuvant Pembrolizumab vs Observation | 1 | E | Total Registrations | 23 | 14 | 8 | 5 | 3 | 2 | 05/01/2019 | 192 | 93 | |
| 23 | 14 | 8 | 5 | 3 | 2 | |||||||||